{"id":"W2544036771","doi":"10.1182/blood.v122.21.1988.1988","title":"FV-162 Is a Novel Orally Bioavailable Proteasome Inhibitor With Improved Pharmacokinetics That Displays Preclinical Efficacy In Vitro and In Vivo","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Bortezomib; Carfilzomib; Proteasome; Proteasome inhibitor; Pharmacology; In vivo; Pharmacokinetics; IC50; Bioavailability; Multiple myeloma; Cytotoxicity; Cell culture; Chemistry; Biology; In vitro; Biochemistry; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001348285,0.0002900275,0.0002620713,0.0001472066,0.00007135604,0.0002125182,0.0001654727,0.00023863,0.001398431],"category_scores_gemma":[0.00006565425,0.0001026446,0.0001123302,0.0001261343,0.0001020598,0.0001694145,0.00009342053,0.0004861349,0.000382172],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000227616,"about_ca_system_score_gemma":0.0001571498,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004626111,"about_ca_topic_score_gemma":0.0008052967,"domain_scores_codex":[0.9999502,0.000008777872,0.000003672467,0.00001213975,0.00001605782,0.000009116703],"domain_scores_gemma":[0.999965,0.000004855715,0.00001116169,0.000003362737,0.000005242254,0.00001036834],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0002499368,0.0001283218,0.0001904967,0.00006162622,0.000006618111,0.00006949714,0.000007993753,0.0002712366,0.9910496,0.00007136696,0.0001859987,0.007707297],"study_design_scores_gemma":[0.0002629196,0.005909089,0.005568375,0.00001059089,0.00004112644,0.001286278,0.00001156782,0.002408209,0.9751955,0.0000647019,0.009230498,0.00001106876],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.978853,0.008477165,0.006392173,0.0002106455,0.00006799664,0.00008262152,0.0006221617,0.0002399662,0.005054125],"genre_scores_gemma":[0.9895532,0.001649829,0.003648697,0.00007815104,0.00002246808,0.00003248999,0.0009158723,0.00001787172,0.004081443],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001398431,"threshold_uncertainty_score":0.004678249,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03172782629800786,"score_gpt":0.3054561033629862,"score_spread":0.2737282770649784,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}